When is it time to buy a stock? One of the best-known pieces of investing advice tells us to buy low and sell high. But what constitutes "low" is relative. A stock near its 52-week high can still be considered at a "low" point, provided there's plenty of upside left. That's why investors shouldn't ignore such stocks.With that as a backdrop, let's look at two companies trading near their 52-week highs and are still worth buying: Abbott Laboratories (ABT 0.20%) and Netflix (NFLX 1.04%).1. Abbott LaboratoriesA ...

Drugmakers Novo Nordisk and Eli Lilly have been making headlines in recent times, thanks to their sought-after weight loss drugs. In fact, the products have become so popular that demand has surpassed supply -- and the companies have been ramping up production to try to keep up.Novo Nordisk's Ozempic and Eli Lilly's Mounjaro are approved for type 2 diabetes, but doctors also have prescribed them for weight loss. And the companies sell the same molecules specifically approved for weight loss under different ...

Mixed reality experience allows blood donors to visit a digital world while remaining fully aware of their surroundings for a safe, relaxing donation 68.4% of pilot study participants who reported pre-donation anxiety said the mixed reality experience helped ease feelings of anxiety 89.2% of donors who tried mixed reality said they were likely to donate blood again Innovation is designed to attract new donors and motivate a younger generation to give blood ABBOTT PARK, Ill., Feb. 1, 2024 /PRNewswire/ -- A ...

The PROTALITY™ brand provides nutritional support for adults pursuing weight loss in the form of a high-protein nutrition shake featuring a blend of fast- and slow-digesting protein designed to feed muscles for up to seven hours As people eat less and lose weight, a portion of what's lost may be from muscle, which is vital to overall health and physical functioning More than 7 in 10 adults are overweight or have obesity in the U.S. and many turn to diets, whether combined with medication, surgery or calori ...

Key PointsMedtech stocks have put in mixed performance over the past two years, offset by dividend payments. Many in the group are trading at value levels, with growth back in the forecast and expected to remain solid over the next two years. Tailwinds are forming that could help lift this market to new highs in 2024 and 2025. 5 stocks we like better than Johnson & JohnsonMed tech stocks have been a mixed bag of results the last two years, with most moving within established trading ranges. The impact of CO ...

A near 2.0% post-earnings decline in Abbott Laboratories (NYSE: ABT) warrants an investment in the health care giant, says Jim Cramer.Cramer’s bullish view on Abbott stockCopy link to sectionHis Charitable Trust bought 275 shares of the medical devices company at $112 each on Monday. Cramer is confident that the weight-loss drugs are not a threat for this Chicago-based maker of FreeStyle Libre (continuous glucose monitoring system).The Mad Money host is bullish on Abbott stock also for the nutrition busines ...

Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Shares of this maker of infant formula, medical devices and drugs have returned +1.8% over the past month versus the Zacks S&P 500 composite's +2.5% change. The Zacks Medical - Products industry, to which Abbott belongs, has gained 1.6% over this period. Now the key question is: Where could the stock be headed in the near ter ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Abbott (ABT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Abbott is a member of our Medical group, which includes 1075 different companies and currently sits at # ...

JHVEPhoto Since I initiated coverage on October 20, 2023, Abbott Laboratories' (NYSE:ABT) stock price has risen by 16.6%, compared to the index return of 14.2%. I highlighted their robust and innovative product pipeline in the introductory article. I believe the company is successfully overcoming challenges related to the COVID-19 pandemic, and I reiterate a 'Strong Buy' rating with a fair value of $115 per share. Recent Result and FY24 Outlook In Q4 FY23, Abbott Laboratories achieved 2.1% organic revenue g ...

Key PointsAbbott Laboratories' share price fell sharply following solid results, setting up a buying opportunity. The company is transitioning back to core organic growth after years of COVID-19 impacts.Analysts are raising their price targets and may drive the stock to break out of its trading range. 5 stocks we like better than Abbott LaboratoriesAbbott Laboratories NYSE: ABT share price fell following its Q4 2023 results, but investors should be cheering the news. The decline is a response to a report th ...